<?xml version="1.0" encoding="UTF-8"?>
<p id="par0100">Lack of specific drugs for COVID-19 compels clinicians to depend on an array of treatment strategies which have been used to treat other viral infections such as: (i) convalescent plasma (
 <xref rid="bib0035" ref-type="bibr">Casadevall and Pirofski, 2020</xref>; 
 <xref rid="bib0045" ref-type="bibr">Chen et al., 2020a</xref>; 
 <xref rid="bib0430" ref-type="bibr">Wong and Lee, 2020</xref>), (ii) Ribavirin a nucleoside analogue that inhibits MERS-CoV replication (
 <xref rid="bib0095" ref-type="bibr">Falzarano et al., 2013</xref>), (iii) Lopinavir/Ritonavir - a combination of protease inhibitors that are used to treat HIV infection, (iv) Remdesivir, a nucleotide analogue that inhibits RNA polymerase of human and zoonotic coronavirus (
 <xref rid="bib0130" ref-type="bibr">Gordon et al., 2020</xref>; 
 <xref rid="bib0415" ref-type="bibr">Wang et al., 2020b</xref>), (v) Favipiravir, known to inhibit RNA polymerase of pathogenic virus (
 <xref rid="bib0115" ref-type="bibr">Furuta et al., 2009</xref>), (v) azithromycin and doxycycline - commonly used antibiotics to inhibit viral replication and IL-6 production (
 <xref rid="bib0355" ref-type="bibr">Sargiacomo et al., 2020</xref>), (vi) drugs that suppress IL-1 or IL-1R (
 <xref rid="bib0060" ref-type="bibr">Conti et al., 2020</xref>).
</p>
